Drug Profile
Research programme: inflammation therapy - AIM Therapeutics
Alternative Names: AIM 101; AIM 501; AIM-002; Ep1B; feG; NeutropelLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator University of Alberta; University of Calgary; University of Western Ontario
- Class Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Cardiovascular disorders; Spinal cord injuries; Type 1 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in Canada (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Canada (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Spinal-cord-injuries in Canada (IV)